Fulcrum Therapeutics is reinventing itself around migraine, agreeing to combine with privately held Slate Medicines in a reverse merger that hands most of the new company to Slate’s backers.
Under the deal, Fulcrum becomes a subsidiary of Slate; the combined company will keep the Slate name and trade on the Nasdaq under the ticker SLTE. It will focus on next-generation migraine therapeutics aimed beyond the widely used CGRP-targeting drugs.
The lead asset
The lead program, SLTE-1009, is a PACAP inhibitor — targeting a different biological pathway than CGRP — licensed from a Chinese drugmaker and designed for patients who don’t respond to approved therapies. It is expected to enter Phase 1 soon, alongside a second antibody program for migraine.
The money and the pivot
Slate raised $130 million initially and announced an additional $245 million financing. Fulcrum, which held about $333 million in cash at the end of Q1 2026, will pay shareholders a cash dividend for net cash above a set threshold; its investors will hold just 5% of the combined company, with Slate’s holding 95%. Fulcrum pivoted after discontinuing its sickle cell drug pociredir when the FDA flagged a risk of secondary blood cancers — echoing safety issues that led to the withdrawal of a similar drug earlier in 2026. Slate CEO Gregory Oakes will lead the merged company, which expects to close the deal by year-end 2026.